BW
VRTX icon

Bravera Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Bravera Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48K Sell
5
-30
-86% -$13.3K ﹤0.01% 333
2026
Q1 		$15.6K Buy
35
+22
+169% +$10.3K 0.01% 263
2025
Q4 		$5.89K Buy
+13
New +$5.6K ﹤0.01% 332

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Bravera Wealth's VRTX Position: Q2 2026 in Review

Bravera Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 86% in Q2 2026, selling an estimated $13.3K and leaving 5 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #333.

Bravera Wealth first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $15.6K in Q1 2026. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bravera Wealth held 5 shares of Vertex Pharmaceuticals worth $2.48K as of Q2 2026.
  • Bravera Wealth sold 30 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Bravera Wealth's portfolio in Q2 2026, its #333 holding.
  • Bravera Wealth first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Bravera Wealth's Vertex Pharmaceuticals position peaked at $15.6K in Q1 2026.
  • 484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bravera Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.